Brokerage firm Citigroup Maintains its rating on Lexicon Pharmaceuticals(NASDAQ:LXRX). In a research note issued to the investors, the brokerage major Raises the price-target to $25.00 per share. The shares have been rated Buy. The rating by Citigroup was issued on Sep 12, 2016.
In a different note, On Aug 5, 2016, Stifel Nicolaus said it Maintains its rating on Lexicon Pharmaceuticals. In the research note, the firm Raises the price-target to $25.00 per share. The shares have been rated ‘Buy’ by the firm. Citigroup said it Initiates Coverage on Lexicon Pharmaceuticals, according to a research note issued on Aug 2, 2016. The shares have been rated ‘Buy’ by the firm.
Lexicon Pharmaceuticals (LXRX) made into the market gainers list on Tuesdays trading session with the shares advancing 1.75% or 0.33 points. Due to strong positive momentum, the stock ended at $19.24, which is also near the day’s high of $19.37. The stock began the session at $18.97 and the volume stood at 6,81,025 shares. The 52-week high of the shares is $19.46 and the 52 week low is $7.65. The company has a current market capitalization of $1,998 M and it has 10,38,65,713 shares in outstanding.
Lexicon Pharmaceuticals(LXRX) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $20.09M. Analysts had an estimated revenue of $12.36M. Earnings per share were $-0.37. Analysts had estimated an EPS of $-0.41.
Several Insider Transactions has been reported to the SEC. On Jun 8, 2016, James F Tessmer (VP, Finance & Accounting) sold 1,500 shares at $15.00 per share price.
Lexicon Pharmaceuticals Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate is an orally delivered small molecule drug candidate as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Company’s sotagliflozin is an orally delivered small molecule drug candidate as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.